Drugs · acquisition-cost intelligence
Inveltys
loteprednol etabonate· ingredient loteprednol etabonate· LOTEPREDNOL ETABONATE 10 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$103.17
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other loteprednol etabonate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| LOTEMAX | $14.49 | −$88.68 |
| loteprednol etabonate | $18.77 | −$84.40 |
| loteprednol etabonate | $30.46 | −$72.71 |
| Lotemax SM | $49.48 | −$53.69 |
| Alrex | $57.93 | −$45.24 |
| Lotemax | $99.75 | −$3.42 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.